Outcome base rates
What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.
0%patentees prevail on the merits
1 merits decision; 1 inconclusive case excluded (small sample)
0 won · 1 lost · Insufficient prior-period data
Win rate by year
Patentee win rate by year of first decision.
- 2025: 0% (0/1)
Win rate by division
Top divisions by merits-decision volume.
- Munich LD0%(n=1)
When patentees lose, why?
Of 1 loss…
100%
Patent invalidated — 1 (100%)No infringement found — 0 (0%)
PI grant rate
—
PI grant rate (conservative)
—
Infringement rate
—
0 infringed · 0 not infringed
Revocation rate
—
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 2
Outcomes by category (detailed)
Stacked breakdown using sharper outcome enums — revocation cases split into revoked_full / revoked_partial / maintained_as_*, etc.
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
- Appeals10
- Infringement4
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
- Court of Appeal10 casesPI grant rate: —Infringement rate: —Revocation rate: —
- Munich LD4 casesPI grant rate: —Infringement rate: —Revocation rate: —
Recent decisions
Most recent decisions in scope.
- 2025-12-12UPC_CFI_146/2024Munich LDProcedural onlyThe Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.
- 2025-12-12UPC_CFI_146/2024Munich LDRevokedThe Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.
- 2025-08-13UPC_CoA_446/2025Court of AppealPI grantedThe Court of Appeal set aside the Lisbon Local Division's refusal to grant provisional measures and ordered a preliminary injunction against Zentiva Portugal prohibiting the making, offering, placing on the market or use of nintedanib products (Nintedanib Zentiva 100mg and 150mg soft capsules) for idiopathic pulmonary fibrosis in 17 UPC Contracting Member States while EP 1 830 843 remains in force. The court held that completion of national HTA/pricing/reimbursement procedures constitutes imminent infringement. Zentiva was ordered to pay EUR 199,000 as an interim award of costs. The request for an information order was denied.
- 2025-07-17UPC_CFI_145/2024Munich LDProcedural onlyProcedural order of the Munich Local Division (presiding judge Zigann) following the interim conference of 17 July 2025 in four consolidated pharmaceutical patent infringement actions by Sanofi and related entities against generics companies (Accord Healthcare, STADA, Dr. Reddy's, Zentiva) concerning EP 2 493 466. Points addressed: EPO Board of Appeal had upheld the patent but had not yet published its written reasoned decision; French parallel first-instance decisions invalidating the French designation were under appeal; defendants wished to comment on EPO BoA written reasons within three weeks of availability. No substantive infringement ruling.
- 2025-05-08UPC_CFI_145/2024Munich LDProcedural onlyProcedural order in consolidated Sanofi v. Accord Healthcare / Dr Reddy's / betapharm infringement proceedings at Munich Local Division. The judge-rapporteur declined to dispose of the case summarily and determined it would be more efficient to await the outcome of pending EPO Board of Appeal proceedings concerning the patent before deciding difficult substantive issues at an oral hearing.
- 2025-05-08UPC_CFI_145/2024Munich LDProcedural onlyProcedural order from Munich Local Division dated 8 May 2025 (unredacted version) in the consolidated infringement proceedings of Sanofi against Accord Healthcare, Stada, Dr. Reddy's and Zentiva regarding EP 2 493 466. The order sets the timetable for further proceedings, confirms the interim conferences (including one focused on EPO BoA appeal outcome on 17 July 2025), and sets the main interim conference for 12 September 2025 and oral hearing dates for 14–17 October 2025. The order also addresses outstanding procedural issues including Zentiva's request to strike Malta from the revocation request, and provides guidance on the panel's preliminary views on damages calculation and infringement.
- 2025-01-14UPC_CFI_145/2024Munich LDProcedural onlyProcedural order from Munich Local Division dated 14 January 2025 regarding R. 262A RoP confidentiality applications filed by defendants (Accord Healthcare, Stada, Dr. Reddy's, Zentiva) in Sanofi's infringement actions concerning EP 2 493 466. The order defines which representative and company personnel on each defendant's side are permitted access to unredacted versions of confidential documents produced in the proceedings.